company background image
ACT

AlzChem GroupXTRA:ACT Stock Report

Market Cap

€242.9m

7D

3.0%

1Y

18.9%

Updated

27 Nov, 2021

Data

Company Financials +
ACT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance5/6
Financial Health5/6
Dividends3/6

ACT Stock Overview

AlzChem Group AG develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally.

AlzChem Group Competitors

Balchem

NasdaqGS:BCPC

US$5.4b

Denka

TSE:4061

JP¥292.8b

Hunan Jiudian Pharmaceutical

SZSE:300705

CN¥6.7b

Price History & Performance

Summary of all time highs, changes and price drops for AlzChem Group
Historical stock prices
Current Share Price€23.90
52 Week High€26.20
52 Week Low€19.40
Beta1.31
1 Month Change8.64%
3 Month Change-4.40%
1 Year Change18.91%
3 Year Change0.42%
5 Year Changen/a
Change since IPO-11.12%

Recent News & Updates

Nov 23
AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AlzChem Group (ETR:ACT) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

AlzChem Group AG ( ETR:ACT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...

Jun 10
Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

Are Investors Undervaluing AlzChem Group AG (ETR:ACT) By 46%?

Today we will run through one way of estimating the intrinsic value of AlzChem Group AG ( ETR:ACT ) by estimating the...

Shareholder Returns

ACTDE ChemicalsDE Market
7D3.0%-6.1%-5.5%
1Y18.9%3.6%15.3%

Return vs Industry: ACT exceeded the German Chemicals industry which returned 3.6% over the past year.

Return vs Market: ACT exceeded the German Market which returned 15.3% over the past year.

Price Volatility

Is ACT's price volatile compared to industry and market?
ACT volatility
ACT Average Weekly Movement2.9%
Chemicals Industry Average Movement4.0%
Market Average Movement4.8%
10% most volatile stocks in DE Market8.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: ACT is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: ACT's weekly volatility (3%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19081,554Andreas Niedermaierhttps://www.alzchem.com

AlzChem Group AG develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand.

AlzChem Group Fundamentals Summary

How do AlzChem Group's earnings and revenue compare to its market cap?
ACT fundamental statistics
Market Cap€242.90m
Earnings (TTM)€26.59m
Revenue (TTM)€419.52m

9.1x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACT income statement (TTM)
Revenue€419.52m
Cost of Revenue€160.66m
Gross Profit€258.86m
Expenses€232.27m
Earnings€26.59m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

Feb 24, 2022

Earnings per share (EPS)2.62
Gross Margin61.70%
Net Profit Margin6.34%
Debt/Equity Ratio0.0%

How did ACT perform over the long term?

See historical performance and comparison

Dividends

3.2%

Current Dividend Yield

29%

Payout Ratio

Valuation

Is AlzChem Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ACT (€23.9) is trading below our estimate of fair value (€92.71)

Significantly Below Fair Value: ACT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ACT is good value based on its PE Ratio (9.1x) compared to the German Chemicals industry average (11.9x).

PE vs Market: ACT is good value based on its PE Ratio (9.1x) compared to the German market (21.3x).


Price to Earnings Growth Ratio

PEG Ratio: ACT is poor value based on its PEG Ratio (1.1x)


Price to Book Ratio

PB vs Industry: ACT is overvalued based on its PB Ratio (3x) compared to the DE Chemicals industry average (2.2x).


Future Growth

How is AlzChem Group forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

8.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ACT's forecast earnings growth (8.3% per year) is above the savings rate (-0.01%).

Earnings vs Market: ACT's earnings (8.3% per year) are forecast to grow slower than the German market (12.2% per year).

High Growth Earnings: ACT's earnings are forecast to grow, but not significantly.

Revenue vs Market: ACT's revenue (5.1% per year) is forecast to grow slower than the German market (5.9% per year).

High Growth Revenue: ACT's revenue (5.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ACT's Return on Equity is forecast to be high in 3 years time (22.4%)


Past Performance

How has AlzChem Group performed over the past 5 years?

3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ACT has a high level of non-cash earnings.

Growing Profit Margin: ACT's current net profit margins (6.3%) are higher than last year (4.3%).


Past Earnings Growth Analysis

Earnings Trend: ACT's earnings have grown by 3.9% per year over the past 5 years.

Accelerating Growth: ACT's earnings growth over the past year (66.5%) exceeds its 5-year average (3.9% per year).

Earnings vs Industry: ACT earnings growth over the past year (66.5%) exceeded the Chemicals industry 54.1%.


Return on Equity

High ROE: ACT's Return on Equity (32.9%) is considered high.


Financial Health

How is AlzChem Group's financial position?


Financial Position Analysis

Short Term Liabilities: ACT's short term assets (€159.2M) exceed its short term liabilities (€82.6M).

Long Term Liabilities: ACT's short term assets (€159.2M) do not cover its long term liabilities (€217.3M).


Debt to Equity History and Analysis

Debt Level: ACT is debt free.

Reducing Debt: ACT has no debt compared to 5 years ago when its debt to equity ratio was 74.8%.

Debt Coverage: ACT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: ACT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is AlzChem Group current dividend yield, its reliability and sustainability?

3.22%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: ACT's dividend (3.22%) is higher than the bottom 25% of dividend payers in the German market (1%).

High Dividend: ACT's dividend (3.22%) is low compared to the top 25% of dividend payers in the German market (3.27%).


Stability and Growth of Payments

Stable Dividend: ACT has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: ACT has only been paying a dividend for 4 years, and since then payments have fallen.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (29.4%), ACT's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: ACT's dividends in 3 years are forecast to be well covered by earnings (30% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Andreas Niedermaier (52 yo)

2.33yrs

Tenure

€827,000

Compensation

Mr. Andreas Niedermaier has been Chairman of Executive Board & Chief Executive Officer at AlzChem Group AG since July 01, 2019 and has been its Member of Management Board since October 20, 2011. He served...


CEO Compensation Analysis

Compensation vs Market: Andreas's total compensation ($USD935.84K) is above average for companies of similar size in the German market ($USD498.59K).

Compensation vs Earnings: Andreas's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ACT's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: ACT's board of directors are seasoned and experienced ( 12.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AlzChem Group AG's employee growth, exchange listings and data sources


Key Information

  • Name: AlzChem Group AG
  • Ticker: ACT
  • Exchange: XTRA
  • Founded: 1908
  • Industry: Specialty Chemicals
  • Sector: Materials
  • Market Cap: €242.904m
  • Shares outstanding: 10.16m
  • Website: https://www.alzchem.com

Number of Employees


Location

  • AlzChem Group AG
  • Dr.-Albert-Frank-Strasse 32
  • Trostberg
  • Bavaria
  • 83308
  • Germany

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/27 18:48
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.